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AbstrAct:
Cancer  initiating  cells  have  been  described  to  be  the  only  cell  population  with 
tumorigenic capacity in glioblastoma multiforme, one of the most aggressive and 
untreatable  cancers.  Recent  work  from  our  group  described  that  NFκB  pathway 
was activated in glioblastoma initiating cells undergoing differentiation, and that 
blockade  of  this  activation  promoted  senescence  of  differentiating  cells.  NFκB 
activation  in  cancer  may  be  the  result  of  either  exposure  to  proinflammatory 
stimuli in the tumor microenvironment or upregulation of the signaling pathway 
by  upstream  regulators.  Appropriate  control  of  NFκB  activity,  which  can  be 
achieved  by  gene  modification  or  pharmacological  strategies,  would  provide 
a  potential  approach  for  the  management  of  NFκB  related  tumors,  including 
glioblastoma.  Here,  we  summarize  the  current  knowledge  of  the  relevance  of 
NFκB  in  cancer  and  its  possible  role  as  a  target  of  therapeutic  intervention.
NFκB SIGNALING
NFκB has been associated with many disease states, 
such as chronic inflammation, cancer, neurodegenerative 
disorders, diabetes and stroke [1; 2]. NFκB proteins 
comprise a family of structurally-related transcription 
factors, including p50 (NFκB1), p65 (RelA), c-Rel, p52 
and RelB, all of which have a conserved N-terminal Rel 
homology domain (RHD) that contains the DNA-binding 
and  dimerization  regions.  Only  p65,  RelB  and  c-Rel 
contain potent transactivation domains within sequences 
C-terminal to the RHD. Therefore, p50 and p52 can not 
act as transcriptional activators by themselves. Dimers of 
these two proteins have been reported to repress NFκB-
dependent transcription in vivo, most likely by competing 
with other transcriptionally active dimers [3]. NFκB is 
present  in  the  cytosol  in  an  inactive  state,  complexed 
with the inhibitory IκB protein. In the classical pathway, 
NFκB  is  regulated  by  two  kinases,  IKKα  and  IKKβ. 
The latter is particularly important as it phosphorylates 
IκB, which is subsequently ubiquitinated and degraded 
by  the  26S  proteasome,  thus  leading  to  the  activation 
of NFκB. Additionally,  the  IKK  complex  requires  the 
regulatory  IKKγ  (NEMO)  subunit. The  result  of  these 
signaling  events  is  the  accumulation  of  the  dimeric 
NFκB transcription factor, containing mainly p50, p65 
and c-Rel, in the nucleus where it is able to transactivate 
different target genes among a large repertoire of more 
than  200  genes  implicated  in  cell  survival/apoptosis, 
cell  growth,  immune  response,  and  inflammation.  A 
number  of  signaling  pathways  converge  on  these  and 
other NFκB regulators, providing multiple possibilities 
for  cancer  cells  to  aberrantly  activate  this  trancription 
factor.  Ever-increasing  evidence  has  demonstrated  that 
both the recruitment of NFκB within the nucleus to target 
genes and the ensuing transcriptional events are actively 
regulated.
The  application  of  knockout  technology  to  the 
NFκB pathway has had a major impact on our current 
understanding of the function of individual components of 
this signaling cascade. Nearly every technique available 
for  the  manipulation  of  the  mouse  genome  has  been 
employed for the analysis of the NFκB signaling pathway, 
including the transgenic overexpression of activators or 
inhibitors of NFκB, conventional and conditional gene 
knockouts and also specific modifications of endogenous Oncotarget 2011; 2:  646 - 653 647 www.impactjournals.com/oncotarget
genes  through  targeted  knock-ins  [4].  Mice  lacking 
IKKγ or IKKβ die early during embryogenesis with liver 
degeneration, a phenotype similar to that of p65-deficient 
animals.  The  analysis  of  cells  lacking  individual  IKK 
subunits led to the identification of two distinct pathways 
regulating NFκB activation. IKKβ and IKKγ are essential 
for NFκB  activation  via  the  canonical  pathway,  which 
is  induced  by  proinflammatory  stimuli  such  as  TNFα, 
IL-1β  and  lipopolysaccharide  (LPS),  and  leads  to  the 
phosphorylation  and  degradation  of  IκB proteins and 
the nuclear accumulation of NFκB. IKKα seems to be 
dispensable for this process, but it regulates, in a IKKγ- 
and IKKβ-independent manner, NFκB activation via the 
alternative pathway. This pathway is activated downstream 
of  receptors  controlling  lymphoid  organogenesis  and 
lymphocyte  development,  such  as  the  lymphotoxin-β 
receptor and the B cell activating factor (BAFF) receptor, 
and induces processing of the NFκB2 (p100) precursor, 
resulting  in  nuclear  accumulation  of  mostly  p52/RelB 
dimers [5]. IKKβ and IKKα kinases also display a degree 
of functional redundancy, exemplified by the presence of 
residual proinflammatory signal-induced NFκB activity in 
IKKβ-deficient cells. 
NFκB IN CANCER
NFκB is one of the major transcription factors 
associated with cancer and it has been implicated in many 
hallmarks of cancer development, including growth factor-
independent proliferation, inhibition of apoptosis, limitless 
replicative potential and tissue invasion and metastasis [6]. 
NFκB also seems to play relevant activities in initiating 
cells. To this end, it has been shown that inhibition of 
this transcription factor maintains pluripotency of mouse 
embryonic initiating cells [7], promotes condrogenesis by 
human mesenchymal initiating cells [8], and controls the 
number of neural progenitor cells [9; 10]. Some cancers 
are caused by viruses that encode activators of the NFκB 
pathway,  which  block  the  cell  death  inherent  in  viral 
transformation [11]. In a variety of hematologic and solid 
tumors, NFκB is constitutively activated by a number of 
different  mechanisms  including  mutation  of  upstream 
components  of  this  pathway  in  tumor  cells  [12].  This 
experimental  evidence  shows  that  the  NFκB is central 
to  the  pathogenesis  of  many  cancer  types,  providing 
the  basis  for  the  development  of  strategies  to  block 
this pathway. NFκB  signaling  is  activated  transiently 
when  normal  B  lymphocytes  respond  to  antigens,  but 
lymphomas accumulate genetic alterations in a number of 
NFκB regulators that constitutively activate this pathway. 
Similarly, normal plasma cells activate NFκB in response 
to  ligands,  but  their  malignant  counterparts,  multiple 
myeloma cells, carry a variety of genetic mutations that 
stabilize NFκB-inducing  kinase  (NIK),  which  leads  to 
constitutive activation of NFκB. Whereas the involvement 
of NFκB activation in hematologic malignancies has been 
well  established,  identifying  a  role  for  NFκB in solid 
tumors required the use of mouse models in which tumor 
induction  depends  on  inflammation,  thus  mimicking 
inflammation-driven cancers in humans [13]. The first one 
was a mouse model for colitis-associated cancer, a type of 
colon cancer that appears in patients with ulcerative colitis, 
a chronic inflammatory bowel disease [14]. These authors 
showed  that  deletion  of  IKKβ in intestinal epithelial 
cells leads to a dramatic decrease in tumor incidence 
without affecting tumor size, which is linked to increased 
epithelial  apoptosis  during  tumor  promotion.  However, 
deletion of IKKβ in myeloid cells promoted a decrease 
in tumor size, most likely due to a reduced expression of 
cytokines that may serve as growth factors for tumor cells. 
Another  inflammation-linked  cancer  is  hepatocellular 
carcinoma (HCC), the most common form of liver cancer. 
This  cancer  mostly  develops  in  the  context  of  chronic 
viral hepatitis. An animal model of HCC, associated with 
chronic liver inflammation, is the Mdr2 knockout mouse. 
This model was used to propose that NFκB constitutes the 
link between inflammation and cancer [15]. The authors 
monitored hepatitis and cancer progression in knockout 
mice,  showing  that  the  inflammatory  process  triggers 
hepatocyte NFκB  through  upregulation  of  TNFα in 
adjacent endothelial and inflammatory cells. Interestingly, 
inhibition of NFκB signaling did not affect early phases 
of hepatocyte transformation, but inducible inhibition in 
later stages of tumor development resulted in apoptosis of 
transformed hepatocytes and failure to progress to HCC. 
However, another mouse model based on the conditional 
deletion of hepatocyte IKKγ exhibited spontaneous liver 
damage and developed HCC even without any injection 
of a carcinogen [16]. Thus, IKKγ was proposed as a tumor 
suppressor in the liver. 
Chronic  inflammatory  disorders  such  as  systemic 
lupus  erythematosus  and  rheumatoid  arthritis  have 
consistently  been  associated  with  the  development  of 
B-cell  non-Hodgkin  lymphoma  [17].  NFκB has been 
shown  to  be  constitutively  activated  in  these  disorders 
and it is considered responsible for the maintenance of 
chronic inflammation due to cytokines such as TNFα, IL-
1, IL-6, and IL-8 [18]. Thus, chronic immune stimulation 
along  with  genetic  and  environmental  factors  and 
some  immunosuppressive  drugs  might  be  involved  in 
lymphomagenesis in these patients. 
There are many other tumors that rarely arise in the 
context of underlying inflammation and yet are dependent 
on inflammatory processes, mainly as a consequence of 
tumor progression. This may be exemplified by prostate 
cancer.  Deletion  of  IKKβ in prostate epithelial cells 
proved to have no effect on prostate cancer development or 
progression. However, deletion of IKKβ in hematopoietic-
derived cells slowed down the development of androgen-
independent prostate cancer and inhibited the appearance 
of metastases [13], most likely due to reduced levels of 
NFκB  target  cytokines  that  may  serve  as  growth  and Oncotarget 2011; 2:  646 - 653 648 www.impactjournals.com/oncotarget
survival  factors  for  cancer  cells.  These  associations 
are of great interest as they provide information about 
mechanisms of tumor development and progression, and 
may help identify novel therapeutic targets. 
NFκB IN GLIOBLASTOMA
The  association  between  NFκB  and  glioblastoma 
(GBM)  is  known  for  more  than  15  years.  A  number 
of  authors  have  described  that  the  NFκB pathway is 
constitutively activated or is upregulated in response to 
different stimuli, mainly cytokines, in GBM cells. EGFR 
gene amplification and overexpression are a particularly 
striking feature of GBM, observed in 40-50% of tumors. 
In approximately 50% of GBMs with EGFR amplification, 
a  highly  oncogenic  EGFR  mutant  (EGFRvIII)  can  be 
detected. This mutant is generated from a deletion of exons 
2 to 7 of the EGFR gene, which results in an in-frame 
deletion of 267 amino acids from the extracellular domain 
of the receptor. EGFRvIII is unable to bind ligand, and 
it signals constitutively. Using GBM cells carrying this 
truncated receptor, it has been shown that EGFR induces 
association between the docking protein Grb2-associated 
binder 1 (Gab1) and the tyrosine phosphatase SHP-2. This 
protein complex appears to be critical for linking EGFR 
to NFκB transcriptional activity via the PI3-kinase/Akt 
signaling axis in GBM cells [19]. In line with this, a recent 
work showed that deletion of IκB has an effect similar to 
that of EGFR amplification in the pathogenesis of GBM 
and is associated with comparatively short survival [20]. 
In this study, 790 human GBM samples were analyzed for 
genetic alterations of IκB and found that this gene is often 
deleted but not mutated in GBM and that deletion of IκB 
and amplification of EGFR showed a pattern of mutual 
exclusivity. This result strengthen the role of the NFκB 
signaling pathway in the pathogenesis and/or progression 
of GBM. Other works have associated activation of NFκB 
with resistance to different cell death strategies such as 
TRAIL,  a  member  of  the  TNF  family  that  selectively 
induces apoptosis in certain tumor cells, and O6-alkylating 
agents that cause DNA damage, the standard therapy of 
GBMs [21; 22]. NFκB activation has also been associated 
with worse prognosis in GBM. A recent work showed 
that the receptor interacting protein 1 (RIP1), an upstream 
activator of the NFκB pathway, negatively regulates p53 
through upregulation of mdm2, a well-known inhibitor of 
this tumor suppressor protein, establishing a mechanistic 
link between NFκB  and  p53  [23].  These  authors  also 
showed that RIP1 and mdm2 are commonly overexpressed 
in GBM, but not in low grade gliomas, and that increased 
expression of RIP1 confers a worse prognosis. A number 
of NFκB  target  genes,  including  cytokines,  cell  cycle 
regulators,  anti-apoptotic  proteins  and  cell  adhesion 
molecules, have been proposed to influence the invasion 
capacity and resistance to chemotherapy of GBM cells. 
All these data support the key role of NFκB in GBM and 
provide a mechanistic explanation for some of the main 
features that make this tumor so aggressive and resistant 
to chemotherapy.   
ACTIVATION  OF  NFκB  IN 
GLIOBLASTOMA  INITIATING  CELLS 
UNDERGOING DIFFERENTIATION
Very recently, we have demonstrated that activation 
of NFκB  is  upregulated  during  differentiation  of 
glioblastoma  initiating  cells  (GICs)  [24].  The  study 
revealed the upregulation of cytokines and chemokines, 
including IL-8, IL-11, IL-6, IL-1β, IL-15, and CCL2 and 
genes  with  diverse  biological  functions,  including  cell 
cycle regulation (Cyclin D1), cell adhesion (CD44) and 
proteolysis (TFPI2, PLAU), which are known targets of the 
NFκB pathway. This result was consistent with the nuclear 
localization of the p65 subunit of NFκB (active state) in 
a high proportion of differentiated cells as compared with 
the progenitor cell population where more than 90% of the 
cells contained p65 within the cytoplasm (inactive state). 
The upregulated activity of NFκB in differentiating GICs 
was further confirmed by the increase in binding of p50-p65 
dimers to a consensus DNA sequence, and a higher level 
of phosphorylated IκB. It has been shown that expression 
of NFκB significantly increased following differentiation 
of  embryonic  stem  (ES)  cells  with  retinoic  acid. 
Additionally, nuclear localization of NFκB in response 
to TNFα, an agonist of NFκB signaling, was evident in 
differentiated, but not in undifferentiated ES cells [25]. 
Similar results have been obtained by other authors [7]. 
Interestingly, overexpression of NFκB proteins promoted 
differentiation, whereas inhibition of NFκB  signaling 
increased  expression  of  pluripotency  markers  [7].  We 
have observed similar results in a reduced number of GIC 
cultures treated with TNFα (Nogueira L and Fernandez-
Luna JL, personal communication). Following treatment 
for up to 16h, GIC-containing neurospheres underwent 
moderate  differentiation  as  assessed  by  morphological 
features. Furthermore, normal differentiation was retarded 
with respect to untreated cells in the presence of a NFκB 
signaling inhibitor. The low activation of NFκB detected in 
GICs suggests that NFκB may be dispensable for survival 
and proliferation of these tumor progenitor cells, which 
correlates with data showing that p65 immunoreactivity 
is abundant in the cytoplasm of the majority of cells 
within  neurospheres  derived  from  embryonic  mouse 
brain, but only occasional weak nuclear localization 
(active state) is detected [9]. Our group also showed that 
blockade of NFκB  in  GICs  undergoing  differentiation 
by using genetic strategies or small-molecule inhibitors 
accelerates maturation, promotes proliferation arrest 
and  induces  cellular  senescence  (polyploidy,  increase 
in  pH2AX-containing  nuclear  foci,  induction  of  β-gal, 
telomere shortening) [24]. There are evidences in other 
cell systems that suggest the role of NFκB in terminal Oncotarget 2011; 2:  646 - 653 649 www.impactjournals.com/oncotarget
differentiation.  For  instance,  signaling  through  the 
receptor activator of NFκB (RANK) not only promotes 
proliferation but also inhibits the terminal differentiation 
of mammary epithelial cells [26]. RANK overexpression 
in  a  transgenic  mouse  model  results  in  increased 
mammary epithelial cell proliferation during pregnancy 
and impaired differentiation of lobulo-alveolar structures, 
suggesting  a  role  for  aberrant  RANK  signaling  during 
breast tumorigenesis. NFκB has also been associated with 
senescence. In line with this, downregulation of NFκB 
has been associated with cellular senescence in a number 
of systems. Treatment of hepatocellular carcinoma cells 
with  rapamycine  plus  5-fluorouracil  led  to  senescence 
accompanied by downregulation of NFκB transcriptional 
activity [27]. Additionally, it has been described that Tid1, 
a homologue of the Drosophila tumor suppressor gene 
l(2)tid, contributes to senescence of rat embryo fibroblasts 
by acting as a repressor of NFκB signaling [28] and that 
replicative cellular senescence of human WI-38 fibroblasts 
was accompanied by a strong decrease in nuclear NFκB 
[29]. 
We  also  showed  that  knockdown  of  Cyclin  D1, 
which is consistently upregulated during differentiation 
of GICs, reproduces part of the phenotype observed by 
inhibition of the NFκB  signaling.  In  good  agreement 
with these findings, Cyclin D1 knockdown in neuroblasts 
promoted a reduction in cell proliferation and an extensive 
neuronal  differentiation  [30].  We  propose  that  direct 
activation  of  the  NFκB  pathway  may  be  an  efficient 
strategy  for  differentiating  glioblastoma-initiating  cells 
to  maintain  their  proliferative  potential,  and  blockade 
of  this  transcriptional  pathway  drives  tumor  cells  into 
senescence.  Further  support  to  this  come  from  c-Neu/
ErbB2-transformed mouse mammary gland cells, cultured 
as  sphere-forming  progenitors,  which  assume  typical 
epithelial appearance following a differentiation stimulus, 
and grow to some extent, but undergo cellular senescence 
following inhibition of NFκB signaling [31]. 
TARGETING  THE  NFκB  PATHWAY  IN 
CANCER
Since  the  identification  of  the  NFκB  signaling 
pathway, many studies demonstrated the association 
between upregulated activity of NFκB and cancer, mostly 
by  protecting  tumor  cells  from  apoptosis.  Therefore, 
this transcriptional pathway participates in the onset or 
progression of many human cancers. It is considered that 
the anti-cancer activities of many anti-inflammatory drugs 
are, at least in part, related to the inhibition of NFκB. 
In addition, many reseacrh groups and companies have 
developed novel compounds acting on the NFκB pathway 
by using a number of systems, including computational 
models  to  virtually  screen  chemical  databases  and 
combinatorial  biosynthesis.  Some  of  these  agents  are 
supposed to be NFκB  specific  (i.e.  IKK  inhibitors) 
while  others  have  wide-range  biological  activities  (i.e. 
proteasome  inhibitors).  Given  the  tight  regulation  of 
NFκB by IκB molecules and the central role of IKKβ 
in phosphorylation and degradation of the inhibitor [32], 
IKKβ is a very promising target for therapeutic strategies 
aiming at interfering with NFκB activation. To this end, 
a number of compounds have been described to inhibit 
IKKβ with a wide range of inhibition activities (Table 
1). Other widely used inhibitors of the NFκB pathway, 
such as Bay 11-7082 and sulfasalazine, have been shown 
to inhibit both IKKα and IKKβ [33-35]. Sulfasalazine 
is  being  tested  in  clinical  trials  for  its  use  in  chronic 
inflammatory  disorders,  such  as  rheumatoid  arthritis. 
In  addition,  a  prospective,  randomised  study  of  the 
Table 1: IKKβ small molecule inhibitors
INHIBITOR *IC50 REFERENCE
BMS-345541 0.3 μM J Biol Chem. 2003;278:1450-6.
IMD-0354 0.28-3.0 μM Blood. 2005;105:2324-31
TPCA-1 0.018 µM J Pharmacol Exp Ther. 2005;312:373-81
PS1145 0.088 μM J Biol Chem. 2005;280:20442-8
MLN120B 0.06-1.0 μM Blood. 2006;107:4266-73
IKI-1 0.07 µM  Cancer Res. 2008;68:9519-24
KINK-1 2.8-21 µM J Natl Cancer Inst. 2008;100:862-75
NSC 676914 17 µM Mol Cancer Ther. 2009;8:571-81
PF-184 0.037 μM  J Pharmacol Exp Ther. 2009;330:377-88
VH01 20.3 μM BMC Bioinformatics. 2010;Suppl 7:S15
LASSBio-1524 20 μM Eur J Med Chem. 2011;46:1245-53
* half maximal inhibitory concentrationOncotarget 2011; 2:  646 - 653 650 www.impactjournals.com/oncotarget
safety and efficacy of sulfasalazine for the treatment of 
progressing malignant gliomas was initiated in 2005 but 
the lack of clinical response and the appearance of side 
effects led to its early termination [36]. Many of the IKKβ 
inhibitors identified so far are being used in cultured cells 
or in animal models and some look promising not only 
because of their capacity to control inflammation but also 
because of their potential to be used as antitumor drugs 
reducing tumor cell survival or inducing sensitisation to 
chemotherapy. Among these, PS1145, MLN120B (both 
from Millennium Pharmaceuticals, Cambridge, MA) and 
BMS-345541 (Bristol-Myers Squibb, Princeton, NJ) have 
been  studied  in  different  tumor  models.  BMS-345541 
sensitises tumor cells derived from mantle cell lymphoma, 
multiple myeloma, neuroblastoma, melanoma and ovarian 
cancer to apoptosis induced by therapeutic agents such as 
TRAIL,  melphalan,  temozolomide  or  carboplatin  [37-
40]. Sensitisation is produced in most cases by reducing 
the expression of NFκB target genes that belong to the 
antiapoptotic machinary of the cell (i.e., Bcl-2 and IAP 
family  members).  Similarly,  PS-1145  has  also  been 
shown to be effective at promoting sensitisation of cells 
from different solid tumors and hematologic malignancies 
to  apoptosis  inducers  [41;  42].  A  novel  glycosylated 
indolocarbazol,  EC-7014,  has  been  recently  identified 
as  a  potent  and  selective  inhibitor  of  IKKβ  [43].  We 
Figure 1: Response of solid tumor-derived cell lines to the IKKβ inhibitor, EC-70124. The small molecule inhibitor was added 
to 24h old cultures of each of the 50 cell lines used in the panel. After 48h of incubation, cells were fixed and stained with sulforhodamine 
B, and the total stain quantitated by absorbance determinations. Through the use of a time 0 control, the 50% lethal concentration (LC50) 
was determined. Those bars that reach the upper limit of the histogram represent LC50 values higher than 100 µM.Oncotarget 2011; 2:  646 - 653 651 www.impactjournals.com/oncotarget
have demonstrated that this inhibitor is able to promote 
replication arrest and senescence of glioblastoma initiating 
cells  undergoing  differentiation  in  vitro.  Moreover, 
intravenous treatment of immunodeficient mice bearing 
human  GIC-derived  tumors  with  EC-70124  induced 
senescence of tumor cells but no ultrastructural alterations 
of the brain parenchyma were detected [24]. These findings 
support the rationale for therapeutic strategies aimed to 
block key factors within the NFκB signaling pathway in 
GBM cells. Consistently, it has been recently described 
that pharmacological inhibition of NFκB decreased the 
viability of GBM cell lines while presented a low toxicity 
to normal astrocytes, which indicated selectivity to cancer 
cells  [44].  In  this  case,  inhibition  was  achived  with 
proteasome inhibitors and other compounds that promote 
an indirect blockade of NFκB. EC-70124 has been tested 
in a panel of 50 human cell lines derived from 8 different 
types of solid tumors: breast cancer, prostate cancer, renal 
cancer,  ovarian  cancer,  melanoma,  CNS  cancer,  colon 
cancer  and  lung  cancer  (Figure  1).  The  best  response 
was achieved in melanoma followed by central nervous 
system (CNS) cancer cells, mainly glioma cells (mean 
LC50 of 3.05 and 4.24 µM respectively) whereas ovarian 
cancer cells were the most resistant to the inhibitor. 
NFκB activity has been shown to be enhanced in many 
cancers, including melanoma, mainly due to deregulations 
in  upstream  signaling  pathways  such  as  Ras/Raf,  PI3-
kinase/Akt, and NIK [45]. Proteasome inhibitors, such as 
PS-341 (bortezomib, velcade), selectively and reversibly 
inhibit the 26S proteasome and prevent the breakdown 
of many regulatory proteins through the inhibition of the 
ubiquitination-proteasome process. One of these proteins 
whose breakdown is impaired is IκB. This presumably 
leads to NFκB inactivation and reversal of the malignant 
phenotype  that  it  regulates.  PS-341  inhibits  growth  of 
melanoma cells in vitro and in vivo either alone or in 
combination  with  temozolomide  [46]. This  proteasome 
inhibitor is already approved for the treatment of patients 
with relapsed multiple myeloma or mantle cell lymphoma, 
and a number of clinical trials are underway to determine 
the value of PS-341 as an effective therapy for malignant 
melanoma.
Increasing evidence indicates the need of preclinical 
studies  and  clinical  trials  using  potent  and  selective 
inhibitors  of  the  kinase  activity  of  IKKs  to  assure  the 
specificity against a key pathway for a number of cancer 
cell  types,  including  glioblastoma.  To  this  end,  there 
are undergoing clinical trials with novel IKK inhibitors 
such  as  SAR113945,  a  small  molecule  inhibitor  from 
Sanofi-Aventis  that  is  being  evaluated  in  patients  with 
knee osteoarthritis. This and other compounds that may 
pass the safety stage, could be adecuate candidates to be 
studied in cancer patients.
UNANSWERED  QUESTIONS  AND 
FUTURE DIRECTIONS
Increasing evidence support the key role of the NFκB 
signaling pathway in the pathogenesis and/or progression 
of GBM. There are many signaling routes that converge 
in the activation of NFκB but their relevance in GBM is 
poorly understood. Among these pathways, DNA damage 
signaling appears to be constitutively activated in gliomas, 
as documented by a number of markers, mostly activation 
of ataxia telangiectasia mutated (ATM) kinase. Upon DNA 
damage, this protein triggers multiple events to promote 
cell  survival  and  facilitate  repair.  ATM  augments  cell 
survival by activating nuclear factor NFκB. Therefore, 
further  investigation  on  the  association  between  ATM 
and NFκB in GBM might expand the targeted therapeutic 
options to avoid NFκB-dependent tumor cell survival and 
thus resistance to chemotherapeutic drugs. Aditionally, a 
detailed study of the vast array of upstream regulators of 
NFκB in GBM cells is still to come. NFκB is emerging 
as a potential target for therapeutic intervention in GBM. 
Although a number of small molecule inhibitors of the 
NFκB pathway, mainly inhibitors of IKK proteins, are 
already available, more specific inhibitors of IKKβ and 
other upstream kinases need to reach clinical studies to 
prove their efficacy in GBM patients.
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